Chronic Lymphocytic Leukemia

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase II trial combining nivolumab (Opdivo) with ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL) and richter transformation (RT) during the American Society of Hematology (ASH) Annual Meeting.<br /> &nbsp;

Combination induction therapy with ibrutinib (Imbruvica) and obinutuzumab (Gazyva) after bendamustine debulking induced a 100% response rate in patients with chronic lymphocytic leukemia (CLL), according to findings from the phase II CLL2-BIG trial.&nbsp;

Lenalidomide as maintenance following first-line immunochemotherapy substantially improves progression-free survival in the treatment of patients with high-risk chronic lymphocytic leukemia (CLL), according to interim analysis of the phase III CLLM1 study.

Findings from the longest follow-up to date evaluating up to 5 years of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) show that the agent is safe and effective.

Jeffrey Jones, MD, MPH, associate professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the benefits of venetoclax in chronic lymphocytic luekemia (CLL).

With treatment for newly diagnosed acute myeloid leukemia remaining essentially unchanged over the last 4 decades, researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for these patients.&nbsp;

Treatment with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica) showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.

Miguel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, and director, Adult Bone Marrow Transplantation Fellowship Program, gives an overview of the PROGRESS II trial in&nbsp;acute leukemia and myelodysplastic syndrome during the ASH Annual Meeting.

The FDA has granted a full approval and label update to ponatinib (Iclusig) for patients with chronic phase (CP), accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

When it comes to adverse events and duration of response, next-generation BTK inhibitors in chronic lymphocytic leukemia compare favorably with ibrutinib.

Immune checkpoint inhibitor development is progressing as treatments for patients with acute myeloid leukemia and myelodysplastic syndrome, with a number of studies currently assessing new combination strategies.

Steven Coutre, MD,&nbsp;professor of medicine, Stanford University School of Medicine, discusses the benefits and drawbacks of the different frontline treatment options for&nbsp;chronic lymphocytic leukemia (CLL).

Alessandra Ferrajoli, MD,&nbsp;discusses the challenge with secondary malignancies in patients with CLL.

William G. Wierda, MD, PhD, discusses&nbsp;provided his expert insight on the frontline treatment of patients with CLL.

Chronic Lymphocytic Leukemia with Steven Coutre, MD

Chronic Lymphocytic Leukemia with Steven Coutre, MD